Vitespen

DB06400InvestigationalVaccines

Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.

Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.Curator reviewed
Code names
HSPPC-96

Resolves to

What you can answer from here — as of September 19, 2023

290Drug interactionsStructured to mechanism, not free text
Sign in
15Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which companies are running trials of Vitespen, in which indications and phases, and which of those programs are still active?

Create a free account or log in to explore the full data card.

Create Account